Biomerica FY26 net sales drop 16% to $4.45 million; dividend, interest and other income more than doubled to $1.23 million - BMRA News | RalliesBiomerica FY26 net sales drop 16% to $4.45 million; dividend, interest and other income more than doubled to $1.23 million
B
BMRA• Other income and liquidity position
- Dividend, interest and other income climbed to USD 1.23 million, driven by a USD 1.1 million Employee Retention Credit benefit.
- Cash and cash equivalents ended at USD 1.31 million; management said existing cash is insufficient for the next 12 months.
Fiscal 2026 sales and expense trends
- Biomerica posted fiscal 2026 net sales of USD 4.45 million, down 16% on lower clinical lab and over-the-counter demand.
- Cost of sales slipped to USD 4.09 million, leaving costs at 92% of net sales versus 91% a year earlier.
- Selling, general and administrative expense rose 6% to USD 4.89 million, while research and development spending fell 23% to USD 788,000.
